Numinus exists to help the world heal, starting with addressing the global crisis in mental health by harnessing the power and promise of psychedelic medicine. Through our integrated model, we are actively contributing to the body of primary and clinical psychedelic research while delivering best-in-class therapeutic protocols across our clinics.

Going beyond breakthroughs

We understand that psychedelics are powerful medicines, but not magic pills. We understand that they can profoundly change lives, families, and communities, and that success requires more than just a breakthrough experience—it also takes careful, sensitive attention to every individual’s story, mindful preparation, and a grounded, realistic plan for what comes after.

Multidisciplinary expertise with human-centred care

Numinus boasts a diverse and interdisciplinary team of professionals, from physicians and psychiatrists to mindfulness teachers, nurses and psychotherapists, researchers and technicians. Our protocols are backed by rigorous science, and delivered by a team that understands that even the best tools still require genuine human care to be effective.

Curiosity and humility

At the core of what we do at Numinus is a deep sense of curiosity and humility about everything we encounter. We know that psychedelics, mindfulness, and embodied practices are not new tools, but rather owe a debt to some very old ways of being and caring for one another. We’re working every day to honour that wisdom and those traditions, and integrating it with the best that modern science has to offer.


View all members


Numinus celebrates Mental Health Week 2021
Mental illness is invisible to the eye — but it’s no less real than physical injury. Now, more than ever, we need to reprioritize and recognize that millions of people […]
May 10, 2021
Numinus builds on strong MAPS Phase 3 trial results through Compassionate Access Trial of MDMA for PTSD
Yesterday, MAPS announced significant, positive results for their Phase 3 clinical trial of MDMA-assisted therapy for PTSD - a major contribution to a growing body of evidence supporting this treatment. […]
May 10, 2021
Numinus Congratulates MAPS on Phase 3 Clinical Trial of MDMA for severe PTSD
1 in 11 Canadians will suffer from PTSD in their lifetime. We urgently need new approaches to mental health care - and now we’re getting closer. Numinus and Dr. Devon […]
May 10, 2021
1 5 6 7 8 9 36
Call us toll-free 1-833-NUMINUS (686-4687)
crosschevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram